Poolbeg Pharma partner with Eurofins Genomics for AI data analysis (Interview)

Poolbeg Pharma plc (LON:POLB) CEO Jeremy Skillington joins DirectorsTalk Interviews to discuss partnering with leading global biopharma services company Eurofins Genomics. Jeremy tells us more about this exciting step in its AI data analysis programme, clarifies the ownership of the human challenge samples, the next step in the data analysis programme, how AI analysis will be used to discover new drugs and explains the benefits of analysing data using AI.

Poolbeg Pharma plc is a clinical stage infectious disease pharmaceutical company, with a novel capital light, clinical model which enables them to develop multiple products faster and more cost effectively than the traditional biotech model.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

More articles like this

Jeremy Skillington Poolbeg Pharma overview

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

PredictViral biomarker platform

Poolbeg Pharma has a unique biomarker platform in development which may be used to identify those at risk of developing severe disease.  Human challenge trials were conducted with front loaded sample collection time points to interrogate the earliest

Poolbeg Pharma launches AI programme with Eurofins Genomics

London-based infectious disease pharmaceutical company, Poolbeg Pharma, has announced their deal with testing and support specialist, Eurofins Genomics, according to Proactive Investors. CEO of Poolbeg Pharma, Jeremy Skillington, says that the aim of this partnership is to complete

Poolbeg Pharma new patent filings for its PredictViral™ platform

Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has provided an update on new patent filings for its PredictViral™ platform that estimates disease severity and contagiousness in people who

Poolbeg Pharma and future pandemic prevention & preparedness

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma – New therapeutics and vaccines

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma partners with Eurofins to complete RNA sequencing

Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has partnered with leading global biopharma services company, Eurofins Genomics, to complete RNA sequencing for Poolbeg of Respiratory Syncytial Virus disease

POLB 001 – Poolbeg Pharma

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.